Development of "Blue Economy": An analysis of the development of China's marine biopharmaceutical industry.

In recent years, many countries have raised marine biomedicine to the level of strategic development, the United States, Britain, Spain and other countries have formulated marine biopharmaceutical industry development plans, increase research and development investment in the field of marine biomedicine, as a "blue economy" growth point to promote.
In contrast, although China's marine strategic emerging industries started late, but since 1978, the National Science and Technology Congress put forward "the development of marine lake and marsh resources, the creation of China's blue pharmaceutical industry" and other strategic ideas, 42 years is also accelerating the cultivation and development of marine biopharmaceutical industry.
, three of the world's 15 marine drugs have been born in China.
. Introduction to marine biopharmaceutical industry The marine biopharmaceutical industry refers to the extraction of active ingredients from marine life and the use of modern biotechnology for the production of marine biochemicals, health care products and genetically engineered drugs.
marine drugs refer to drugs developed using modern scientific methods and techniques based on marine life and marine microorganisms.
Most of the existing marine drugs belong to the category of natural drugs, that is, directly extracted from marine life active ingredients, but also some marine living active ingredients obtained through synthetic or biotechnology conversion, can be broadly divided into the following categories: 1. Chinese medicine: Marine Chinese medicine is under the guidance of chinese medicine theory, marine medicinal organisms in accordance with the requirements of China's new drug approval into Chinese medicine.
In most cases, marine medicinal organisms, according to their sexual taste and efficacy, are more likely to be combined with other Chinese herbal medicines; Marine drugs derived from marine organisms and microorganisms using biotechnology such as genetic engineering, protein engineering, cell engineering and fermentation engineering, which are then developed by synthetic or semi-synthetic methods, are classified as biological products.
II. The development of China's marine biopharmaceutical industry 1. The rapid development of marine biopharmaceutical industry, innovative products to fill the gap in the market because marine natural products have rich structural diversity, wide range of activity and high intensity, at the same time has a greater class of pharmaceutical, marine drugs and marine biological products research and industrialization has now become a hot area of competition between marine powers.
, vigorously promoting the development of the national marine economy is a major strategic deployment to actively expand the space for the development of the national economy and safeguard the rights and interests of the state, and a major measure to transform the mode of economic development.
In recent years, China's marine biopharmaceutical industry has shown a rapid development trend, with the value added of China's marine biopharmaceutical industry reaching 6.7 billion yuan in 2010, reaching 30.2 billion yuan in 2015, and the marine biopharmaceutical industry achieving an annual value-added of 44.3 billion yuan in 2019, an increase of 7.0% over the previous year.
figure 1: China's marine biopharmaceutical industry value-added data source: China's marine economic statistics bulletin for the product market process, China's marine drug research and development has achieved more remarkable results, has been approved for listing a variety of marine drugs, including antiviral, anticoagulant, blood lipid reduction, immunomodulation, sedation, anesthesia, delayed atherosclerosis, etc. More than 40 kinds of products, including GV971, sodium alginate, glycol hydrochloride, acid, pufferfish toxin, fish liver oil, etc., including GV-971, which has just been approved for sale, are innovative drugs developed independently in China and have independent intellectual property rights, and also fill the gap in the field of Alzheimer's disease for 17 years without new drugs on the market.
china's marine biopharmaceutical industry patent output has also shown year-on-year growth trend.
2014-2019, the number of marine biopharmaceutical patents disclosed increased year by year.
40 in 2019 from 3 in 2014, a more than 10-fold increase.
as of August 2020, there will be 25 patents for public inventions in 2020, and the number of patents for inventions will exceed 40 in 2020.
table 1: China has independent property rights of marine biopharmaceutical products (partially) Source: Firestone creation according to public information collated figure 2: 2014-2019 marine biopharmaceutical patents open quantity data source: State Intellectual Property Office 2. After more than 40 years, China's marine biopharmaceutical industry under the policy of holding into the "ascending stage" China is one of the first to use marine life as a drug, marine biopharmaceutical industry development can be divided into three stages: From the mid-1970s to the end of the 1980s, since the National Conference on Science and Technology put forward strategic ideas such as "developing marine lake and marsh resources and creating China's blue pharmaceutical industry", marine drug research began to attract attention, and gradually incorporated into the national plan, the development of marine biopharmaceutical industry began to take off; Teaching institutions, the establishment of academic organizations and marine pharmaceutical professional publications, a variety of marine pharmaceutical products and functional food, marine biopharmaceutical industry system is basically complete, industrial development has begun to take shape;
In 2018, Mr. Guan Huashi, a member of the Chinese Academy of Engineering, initiated the development plan of China's "Blue Pharmaceutical Library", which aims at the rise of marine biopharmaceutical industry on the basis of nearly 80 years of experience and achievements in marine drug research and development, and brings together the international first-class marine drug research and development team to carry out systematic, comprehensive and orderly development of marine bio-resources.
: China's marine biopharmaceutical industry development in the third stage to further promote the development of marine biopharmaceutical industry, now China in a number of plans for its development goals, while policy encouragement and support.
the outline of the 13th Five-Year Plan for National Economic and Social Development put forward the strategic deployment of "expanding the blue economic space", which put forward new and higher requirements for the development of marine economy during the 13th Five-Year Plan period.
In addition, "13th Five-Year Plan" special plan for scientific and technological innovation in the marine field, "13th Five-Year Plan" marine economic development plan of Shandong Province, "Plan for the main functional area of the ocean in Jiangsu Province", "Development Plan for the Blue Economic Pilot Zone of the Fujian Strait" "Qingdao Marine Biopharmaceutical Industry Development Plan" and a series of plans and policies, different regions have put forward the development goals and specific measures of the marine biopharmaceutical industry, and strongly support the development of the industry.
table 3: China's marine biopharmaceutical industry development policy document (partial) Source: Firestone creation according to public information collation 3. Policy and market dual drive, China's marine biopharmaceutical industry has broad prospects for development at present China's economic level continues to improve, the population is huge, the demand for medicine is increasing, while the quality of medicine is also higher and higher requirements.
Marine life, because of its unique nutritional value, contains a variety of biologically active substances, which can effectively prevent and treat cardiovascular diseases, promote cell metabolism, fight cancer, protect the normal function of cells in the body, and delay the aging of the brain.
Moremore, as an emerging industry that began to develop internationally in the 1940s, it is predicted that 90.4-92.6% of marine bio-sourced compounds are still unsolveed and that the oceans are a vast treasure trove of pharmaceutical resources for humans.
background, the overlay policy and holding factors, China's marine biopharmaceutical industry will usher in a broad development prospects.
CIC consultants forecast that China's marine biopharmaceutical industry will grow at a compound rate of about 12.37 percent in 2018-2022, and the value added of the industry will reach 70 billion yuan in 2022.
figure 4: 2018-2022 China's marine biopharmaceutical industry value-added forecast data source: CIC Consultants Industrial Research Center III, China's marine biopharmaceutical industry competition pattern with the rise of the blue economy boom, Shandong, Guangdong, Zhejiang, Fujian and other coastal provinces have increased investment in the marine biopharmaceutical industry, as a blue economic growth point to accelerate the promotion.
the prototype of China's "blue medicine bank" is gradually emerging in Qingdao.
Shandong Province will include the new pharmaceutical industry in the "four new sea" strategy, will focus on accelerating the development of marine biomedicine, Qingdao as the national marine science and technology innovation, is the national marine biopharmaceutical research and development, production of the main gathering place, has successfully developed 5 marine drugs, more than 200 marine life functional products, "marine characteristics of the oligarchic sugar system Preparation technology (sugar bank construction) and application development won the first prize of national scientific and technological invention, anti-dementia drug GV-971 relying on China Ocean University research and development success and was approved for listing, anti-cardiovascular drug PSS (sodium alginate) into the secondary development stage, a number of marine candidate drugs into the pre-clinical research stage.
has become a national marine biotechnology and marine drug research center with Shanghai, Xiamen and Guangzhou.
Province to vigorously implement the strategy of scientific and technological development, marine biomedicine personnel training has become a system.
guangdong coastline of 3368 kilometers, is China's coastline length of the second largest province, with unique marine resources.
Guangdong Province marine biopharmaceutical industry is mainly distributed in the Pearl River Delta region, Guangdong, eastern Guangdong and western regions, with many universities and scientific research institutions, such as Zhongshan University, the Chinese Academy of Sciences South China Sea Institute of Ocean Research, and has more marine biopharmaceutical industry-related patents and scientific research results, the training of relevant personnel has formed a more complete system.
driven by China's realization of the blue economy, Guangdong Province has gradually realized the strategy of moving from a large marine province to a strong marine province.
the development of marine life enterprises in Zhejiang Province, and initially formed an industrial pattern of marine functional food and marine medicine.
In recent years, Zhejiang has accelerated the construction of marine biopharmaceutical industrial park, the public pilot workshop of marine high-tech achievements, the exploration and utilization of biological species resources of Zhejiang Oceanographic College, the National Marine Facilities Breeding Engineering and Technology Research Center, etc. have been completed and operated one after another, and the research and development production capacity of marine functional food and marine drugs has begun to take shape, initially forming local characteristics and industrial amassing.
Zhoushan, using the position and industrial advantages, has formed a clear industrial characteristics, the existing polyenecon, ammonia sugar meth tablets, sleetene and other more than 10 kinds of leading products;
, Fujian Province, has become a new high ground for marine biomedicine by actively exploring the development model of marine industry.
, Fujian Province marine medicine and biological industry is mainly distributed in Fuzhou, Xiamen, Zhangzhou, Quanzhou and other coastal areas.
in recent years, Xiamen City actively explores the "policy chain, innovation chain, industrial chain, financial chain" four-chain integration of industrial development model, the introduction of "on accelerating the implementation of marine economic development", "Xiamen City Marine Economic Development Work Programme" "Xiamen City Marine and Fisheries Development Special Fund Management Measures", and so on, clearly put forward the marine biopharmaceutical industry as a priority for the development of marine strategic emerging industries.
Under the guidance of the government and policy support, Xiamen City currently has nearly 50 marine biopharmaceutical enterprises, including 35 marine pharmaceutical manufacturing enterprises, marine functional food manufacturing enterprises 11, initially formed a number of international leading technology emerging enterprises.
, Guangxi vigorously promote the integration of marine biopharmaceutical industry and research, accelerate the "blue medicine bank" march.
With abundant marine medicinal biological resources, integrating the forces of industry, science and research, Guangxi has been accelerating its technology-based research and development capabilities, expanding industrial scale and increasing industrial value added, and the marine biopharmaceutical industry will achieve an increase of 200 million yuan in 2017, with great potential.
In recent years, with the help of the development tide of the national strategy "blue economy", Guangxi Marine Biomedicine has now formed a key research team and key technical support with Guangxi University of Traditional Chinese Medicine Marine Medicine Research Institute, Guangxi Marine Biotechnology Key Laboratory and Guangxi University Marine College as the core.
4. The development prospect of marine biopharmaceutical industry has found 35,000 marine natural products, more than half of which have biological activity, far higher than the biological activity of natural products of land animals and plants, marine can provide a large number of drug-led compounds, marine biopharmaceutical industry has formed a new sunrise industry.
Europe, the United States, Japan and other developed countries each year to invest 10 billion U.S. dollars in the development of marine bioenzyme, the United States Johnson and Johnson, Xerl hui and other companies have invested heavily in the development of bio-compatible marine biomedical medical materials.
Although China has been supporting the marine pharmaceutical industry in recent years from the policy and top-level design, and the scale of the industry has steadily increased, the development of the marine biopharmaceutical industry still lags far behind the world's leading countries and has not yet formed an internationally competitive industrial cluster.
The main gap in China's marine biopharmaceutical industry stems from (1) insufficient investment in marine biopharmaceutical research and development and little independent innovation;
Therefore, the government needs to increase financial input, introduce relevant preferential policies, and support the construction of public service platforms in the field of marine biopharmaceutical industry, strengthen the training of marine biomedical personnel, encourage enterprises to explore the international market, and gradually enhance the strength of industrial research and development and market space, so as to promote the sustainable development of the industry.
author of the book, Xin Mingyu.